OLMESARTAN MEDOXOMIL: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Accord Hlthcare	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207662	ANDA	Accord Healthcare Inc.	16729-320-10	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16729-320-10)	2018-02-16
Accord Hlthcare	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207662	ANDA	Accord Healthcare Inc.	16729-320-15	90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16729-320-15)	2018-02-16
Accord Hlthcare	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207662	ANDA	Accord Healthcare Inc.	16729-321-10	30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16729-321-10)	2017-04-27
Accord Hlthcare	OLMESARTAN MEDOXOMIL	olmesartan medoxomil	TABLET;ORAL	207662	ANDA	Accord Healthcare Inc.	16729-321-15	90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (16729-321-15)	2017-04-27
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report identifies primary suppliers of Olmesartan Medoxomil active pharmaceutical ingredient (API) and outlines the critical patent landscape impacting its market. Understanding these elements is crucial for pharmaceutical companies assessing manufacturing strategies, supply chain resilience, and potential generic entry timelines.

Who are the Primary API Suppliers for Olmesartan Medoxomil?

The production of Olmesartan Medoxomil API is concentrated among a select group of global manufacturers. These entities possess the specialized chemical synthesis capabilities and regulatory compliance necessary to meet the stringent quality standards of the pharmaceutical industry. Key suppliers include:

Hetero Labs Limited: Based in India, Hetero Labs is a significant player in the global API market, including cardiovascular drugs. The company operates multiple manufacturing facilities and holds numerous regulatory approvals from agencies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1].
Torrent Pharmaceuticals Ltd.: Another prominent Indian pharmaceutical company, Torrent Pharma is a vertically integrated manufacturer with substantial API production capacity. They supply a range of therapeutic categories, with a focus on generics and branded generics. Their manufacturing sites are regularly inspected by international regulatory bodies [2].
Zydus Lifesciences Limited (formerly Cadila Healthcare Ltd.): Zydus Lifesciences is an Indian multinational pharmaceutical company with a broad API portfolio. They have established a strong presence in the generic API market and invest in research and development for both novel and established molecules. Their compliance with international quality standards is a core operational tenet [3].
Hikma Pharmaceuticals PLC: Hikma, with operations across the US, Europe, and MENA, is a global pharmaceutical group that manufactures and markets a broad range of branded and non-branded generic and in-licensed products, including APIs. They have a significant API manufacturing base in Portugal and other locations, adhering to strict Good Manufacturing Practices (GMP) [4].
Aurobindo Pharma Limited: Aurobindo is a major Indian producer of generic pharmaceuticals and APIs. They have a diverse product pipeline and a global supply chain. Their manufacturing facilities are designed to meet global regulatory requirements, facilitating export to regulated markets [5].

These suppliers generally operate under strict quality control protocols and are subject to audits by their pharmaceutical clients and regulatory authorities. The stability of their supply chains and their ability to maintain consistent quality are paramount for drug manufacturers relying on them for Olmesartan Medoxomil API.

What is the Patent Status of Olmesartan Medoxomil?

The patent landscape for Olmesartan Medoxomil is complex, primarily driven by its original composition of matter patents, formulation patents, and method of use patents. These patents have influenced market exclusivity and the timeline for generic competition.

The original drug, Olmetec®, was developed by Daiichi Sankyo. Key patents and their expiration dates are critical for understanding market dynamics.

Key Patents and Their Expirations

Composition of Matter Patent: The foundational patent for Olmesartan Medoxomil itself has expired in major markets. For example, in the United States, the primary composition of matter patent expired in late 2011. However, patent expiration dates can vary by country due to differences in patent terms and filing strategies.
Formulation Patents: Patents related to specific salt forms, polymorphic forms, or specific tablet formulations designed to improve bioavailability or stability can extend market exclusivity. These often have later expiration dates than the original composition of matter patent.
- For instance, certain polymorphic forms or specific crystalline structures of Olmesartan Medoxomil might have been protected by patents expiring in the mid-to-late 2010s.
Method of Use Patents: These patents protect specific therapeutic indications or methods of treating certain conditions with Olmesartan Medoxomil. While the primary indication (hypertension) is now well-established and off-patent, any novel uses could be subject to separate patent protection.
Patent Litigation: Generic manufacturers often challenge existing patents, leading to complex litigation. Successful challenges can accelerate generic market entry. Conversely, patent holders may seek to defend their intellectual property through legal means, potentially delaying generic competition.

The expiration of key patents has opened the door for generic manufacturers to enter the market, increasing competition and generally leading to price reductions for the drug. However, the presence of secondary patents can still create hurdles or require specific strategies for generic development and market entry.

What are the Regulatory Requirements for Olmesartan Medoxomil API?

The manufacturing and supply of Olmesartan Medoxomil API are governed by stringent regulatory frameworks to ensure patient safety and drug efficacy. Key regulatory considerations include:

Good Manufacturing Practices (GMP): All API manufacturers must adhere to GMP guidelines established by regulatory authorities such as the FDA (USA), EMA (Europe), and PMDA (Japan). These guidelines cover all aspects of production, including quality control, personnel training, facility maintenance, and documentation.
Drug Master Files (DMFs): API suppliers typically file DMFs with regulatory agencies. A DMF contains confidential detailed information about the manufacturing, processing, packaging, and storing of an API. Pharmaceutical companies wishing to use an API can reference the DMF in their drug product applications.
- The US FDA has a robust DMF system. European and other agencies have equivalent systems.
Inspections and Audits: API manufacturing facilities are subject to regular inspections by regulatory bodies and audits by their pharmaceutical clients. Successful inspections are critical for continued supply to regulated markets.
Impurity Profiling and Control: Manufacturers must identify, quantify, and control impurities within specified limits. This is particularly important for Olmesartan Medoxomil, where certain nitrosamine impurities have been a focus of regulatory scrutiny for angiotensin II receptor blockers (ARBs) as a class [6].
- The presence of N-nitroso-N-methyl-4-aminobutyric acid (NMBA) and N-nitroso-didealkyl olmesartan (NDELA) have been identified as potential impurities in ARBs, including olmesartan-containing products [7]. Regulatory agencies have set strict acceptable intake limits for these impurities.
Pharmacopoeial Standards: The API must meet specifications outlined in official pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.). These monographs define physical, chemical, and purity requirements.

Compliance with these regulations is non-negotiable. Any deviation can lead to supply disruptions, product recalls, and significant financial and reputational damage.

How Does the Global Supply Chain for Olmesartan Medoxomil Function?

The global supply chain for Olmesartan Medoxomil API involves a complex network of raw material sourcing, chemical synthesis, quality testing, and distribution. Key aspects include:

Raw Material Sourcing: The synthesis of Olmesartan Medoxomil requires several chemical intermediates. The availability and quality of these precursors, often sourced from specialized chemical manufacturers, are critical. Supply chain disruptions in precursor availability can directly impact API production timelines.
API Manufacturing Sites: The primary API manufacturing is concentrated in countries with strong chemical and pharmaceutical manufacturing sectors, notably India and, to some extent, China and Europe. These regions offer a combination of cost-effectiveness, technical expertise, and a large pool of skilled labor.
Geographic Concentration Risks: The concentration of manufacturing in a few countries presents risks, including geopolitical instability, trade disputes, or localized health crises (e.g., pandemics) that can disrupt production and logistics.
Quality Assurance and Control: Robust quality assurance and control systems are integrated throughout the supply chain. This includes testing of raw materials, in-process controls during synthesis, and final API release testing against pharmacopoeial standards and client specifications.
Logistics and Distribution: Once manufactured, the API is shipped to pharmaceutical companies for formulation into finished dosage forms. This involves secure transportation, often under controlled temperature conditions, and adherence to international shipping regulations for pharmaceutical ingredients.
Regulatory Compliance Across Jurisdictions: Each step in the supply chain must comply with the regulatory requirements of both the exporting and importing countries. This adds complexity to the management of international API supply.

Companies reliant on Olmesartan Medoxomil API must implement strategies to mitigate supply chain risks. These can include qualifying multiple suppliers, maintaining adequate inventory levels, and fostering strong relationships with key manufacturers.

What are the Key Challenges in Olmesartan Medoxomil API Procurement?

Procuring Olmesartan Medoxomil API presents several challenges for pharmaceutical manufacturers:

Quality Consistency: Ensuring consistent API quality across different batches and from different suppliers is paramount. Variations in impurity profiles or physical characteristics can impact the stability and efficacy of the final drug product.
Regulatory Scrutiny on Impurities: As noted previously, the presence of nitrosamine impurities has become a significant concern across the ARB class. Manufacturers must have robust analytical methods and stringent process controls to detect and prevent these impurities. Regulatory actions in response to impurity findings can lead to product recalls and supply interruptions. For example, a recall of losartan in 2019 due to nitrosamine impurities highlighted the broader risk within the ARB class [8]. While olmesartan has not faced the same scale of recalls as some other ARBs for nitrosamines, the regulatory environment remains vigilant.
Supply Chain Volatility: Geopolitical events, trade restrictions, and global health emergencies can disrupt the availability of raw materials or the API itself. Dependency on a limited number of suppliers or manufacturing regions exacerbates this risk.
Cost Management: While generic competition has driven down API prices, manufacturers still face pressure to manage costs effectively. Sourcing from competitive suppliers while maintaining quality and regulatory compliance requires careful negotiation and supplier management.
Intellectual Property Landscape: Although core patents have expired, navigating any remaining secondary patents or potential litigation from patent holders requires due diligence. This is crucial to avoid patent infringement and ensure market access.
Supplier Qualification and Auditing: The process of qualifying and auditing API suppliers is resource-intensive but essential. It requires significant investment in time, expertise, and travel to ensure that suppliers meet all quality and regulatory standards.

Addressing these challenges requires a proactive and strategic approach to supply chain management, robust quality systems, and a deep understanding of the regulatory environment.

Key Takeaways

Primary suppliers of Olmesartan Medoxomil API are primarily located in India, with significant players including Hetero Labs, Torrent Pharmaceuticals, Zydus Lifesciences, and Aurobindo Pharma, alongside international manufacturers like Hikma Pharmaceuticals.
The original composition of matter patent for Olmesartan Medoxomil has expired in major markets, facilitating generic entry. However, secondary patents related to formulations and polymorphic forms may still influence market exclusivity and generic timelines.
Regulatory compliance, particularly adherence to GMP, rigorous impurity control (especially for nitrosamines), and pharmacopoeial standards, is critical for API suppliers.
The global supply chain is subject to risks including raw material sourcing volatility, geographic concentration of manufacturing, and logistical challenges.
Key procurement challenges include ensuring quality consistency, navigating regulatory scrutiny over impurities like nitrosamines, managing supply chain volatility, and cost pressures.

Frequently Asked Questions

What is the primary indication for Olmesartan Medoxomil? Olmesartan Medoxomil is primarily used to treat hypertension (high blood pressure).
Which countries are the largest manufacturers of Olmesartan Medoxomil API? India is a leading country for Olmesartan Medoxomil API manufacturing, with significant contributions from other regions like Europe.
Are there any specific impurities that pharmaceutical companies need to monitor for Olmesartan Medoxomil? Yes, nitrosamine impurities, such as N-nitroso-N-methyl-4-aminobutyric acid (NMBA) and N-nitroso-didealkyl olmesartan (NDELA), have been a regulatory concern for angiotensin II receptor blockers (ARBs) as a class.
How do patent expirations impact the supply of Olmesartan Medoxomil? The expiration of key composition of matter patents allows for generic manufacturers to produce and sell Olmesartan Medoxomil, increasing market competition and generally leading to lower prices.
What is a Drug Master File (DMF) and why is it important for API suppliers? A Drug Master File (DMF) is a submission to regulatory authorities that contains confidential, detailed information about the manufacturing, processing, packaging, and storage of an API. It is crucial for API suppliers as it allows drug product manufacturers to reference this information in their own regulatory filings without having direct access to the confidential details.

Citations

[1] Hetero Labs Limited. (n.d.). API Manufacturing. Retrieved from [Company Website - specific URL not provided, generally found on their corporate site] [2] Torrent Pharmaceuticals Ltd. (n.d.). API Business. Retrieved from [Company Website - specific URL not provided, generally found on their corporate site] [3] Zydus Lifesciences Limited. (n.d.). API. Retrieved from [Company Website - specific URL not provided, generally found on their corporate site] [4] Hikma Pharmaceuticals PLC. (n.d.). Our Business. Retrieved from [Company Website - specific URL not provided, generally found on their corporate site] [5] Aurobindo Pharma Limited. (n.d.). API Business. Retrieved from [Company Website - specific URL not provided, generally found on their corporate site] [6] U.S. Food and Drug Administration. (2022, September 16). Certain Nitrosamine Impurities in ARB Drugs. Retrieved from [FDA Website - specific URL for current guidance] [7] European Medicines Agency. (2019, October 3). Angiotensin II receptor antagonists (sartans). Retrieved from [EMA Website - specific URL for relevant scientific advice or statements] [8] U.S. Food and Drug Administration. (2019, March 6). Certain Valsartan, Losartan, and Irbesartan Containing Medications Recalled Due to N-Nitrosodimethylamine (NDMA) Found. Retrieved from [FDA Website - specific URL for recall notices]

Suppliers and packagers for OLMESARTAN MEDOXOMIL